Skip to main content
Menu
US
htrf-treating-solid-tumors-1920x400.jpg
Literature - Publication Review

Strengthen cancer treatment search with HTRF™, AlphaLISA™, and DELFIA™-TRF kits

Investigating therapeutic candidates’ effects on two solid cancers

In oncology, we classify cancers into two general categories: blood cancers and solid tumor cancers. The latter are cancer cell stacks that can aggregate in either epithelial tissues, in which case they form carcinomas, or in supportive tissues, to develop into sarcomas. Each has its own special features, but both are challenging for researchers with, among others, a lack of expression of tumor-specific antigen targets in these cancers. This note highlights two studies that used biochemical and cell-based assays to help characterize and develop new treatments to target Non-Small Cell Lung Carcinoma (NSCLC) and Soft Tissue Sarcomas (STS).

Featured in this note:

  • Assay principle and workflow
  • Consistent results (data and graphs)
  • Informative materials and methods, including references

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Strengthen cancer treatment search with HTRF™, AlphaLISA™, and DELFIA™-TRF kits